As of today (2024-04-24), Compass Pathways's share price is $8.005.
Compass Pathways's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.99. Hence, Compass Pathways's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Compass Pathways's Price-to-Free-Cash-Flow or its related term are showing as below:
CMPS's Price-to-Free-Cash-Flow is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 18.22 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -29.20% per year.
During the past 6 years, Compass Pathways's highest 3-Year average Free Cash Flow per Share Growth Rate was 7.90% per year. The lowest was -44.50% per year. And the median was -43.60% per year.
Compass Pathways Price-to-Free-Cash-Flow Historical Data
The historical data trend for Compass Pathways's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Compass Pathways's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways Price-to-Free-Cash-Flow Distribution
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Price-to-Free-Cash-Flow falls into.
Compass Pathways's Share Price of today is $8.005.
Compass Pathways's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.99.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Compass Pathways Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Compass Pathways's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Pathways (Compass Pathways) Business Description
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPS has been successfully added to your 